2. Search Result
Search Result
Results for "

urothelial bladder cancer

" in MedChemExpress (MCE) Product Catalog:

6

Inhibitors & Agonists

2

Natural
Products

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-159642
    Dabogratinib

    TYRA-300

    		 FGFR ERK Metabolic Disease Cancer
    Dabogratinib (TYRA-300) is an orally active, selective FGFR3 inhibitor with an IC50 of 11 nM. Dabogratinib exhibits antitumor activity against urothelial carcinoma and solid tumors. Dabogratinib downregulates the FGFR3 and ERK1/2 signaling pathways, and induces tumor growth inhibition and regression in FGFR3-altered xenograft models. Dabogratinib promotes chondrocyte proliferation and differentiation, drives endochondral bone formation and overall body growth, partially restores long bone proportions, and improves craniofacial and spinal morphology. Dabogratinib can be used for the research of metastatic urothelial carcinoma, achondroplasia and hypochondroplasia .
    Dabogratinib
  • HY-W755252
    N-Butyl-N-(4-hydroxybutyl)nitrosamine

    BBN

    		 DNA Alkylator/Crosslinker Cancer
    N-Butyl-N-(4-hydroxybutyl)nitrosamine is a potent mutagen that can cause high-level of mutagenesis specifically in the epithelial cells (urothelial) of the urinary bladder. N-Butyl-N-(4-hydroxybutyl)nitrosamine is used to induce bladder cancer in rodents .
    N-Butyl-N-(4-hydroxybutyl)nitrosamine
  • HY-126566
    Trichostatin C

    		Fungal HDAC Apoptosis Infection Cancer
    Trichostatin C is an inhibitor for histone deacetylase (HDAC), induces apoptosis and arrests cell cycle at G2/M phase, and exhibits anticancer activity against lung cancer and urothelial bladder cancer . Trichostatin C induces differentation of Friend leukemic cells . Trichostatin C exhibits antifungal activity .
    Trichostatin C
  • HY-174981
    LC-MF-4

    		PROTACs FGFR ATP Synthase Cancer
    LC-MF-4 is a selective FGFR3 PROTAC degrader with a DC50 of 30.89 nM in KMS-11 cells. LC-MF-4 inhibits the metabolic function of FGFR3-TACC3 fusion positive cancers with reduction of ATP synthesis and inhibition of mitochondrial biogenesis genes. LC-MF-4 has potent antitumor activity in the Ba/F3-FGFR3-TACC3 xenograft mice model. LC-MF-4 can be used for FGFR3-altered cancers like bladder cancer and urothelial carcinoma (UC) research . Pink: FGFR3 ligand (HY-175414); Blue: VHL ligase ligand (HY-125905); Black: linker (HY-Y1224)
    LC-MF-4
  • HY-182747
    HDAC6-IN-79

    		HDAC Autophagy Apoptosis Cancer
    HDAC6-IN-79 is a HDAC6 inhibitor with an IC50 of 98.40 nM, and it also exhibits inhibitory activity against other HDAC subtypes (HDAC1: 639.0 nM, HDAC2: 798.9 nM, HDAC8: 865.7 nM, HDAC4: 1187 nM). HDAC6-IN-79 induces acetylation of α-tubulin and histone H3, reduces the viability of cancer cells, activates the autophagy pathway and induces apoptosis. HDAC6-IN-79 can be used for research related to urothelial carcinoma (bladder cancer) .
    HDAC6-IN-79
  • HY-N19113
    Emindole SB

    		Endogenous Metabolite Infection Cancer
    Emindole SB is an anticancer agent. Emindole SB can be isolated from Penicillium species. Emindole SB exerts anticancer effects against ovarian cancer, breast cancer and lymphoma. Emindole SB shows no toxicity to Caenorhabditis elegans. Emindole SB can be used in studies related to ovarian cancer, lymphoma and breast cancer .
    Emindole SB

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: